Assessing the Value of Early-Stage PE Investments

 

Valuing venture or early-stage private equity investments can be tricky since they don’t typically have revenues or cash flow yet. As such, applying traditional valuation methodologies like considering discounted cash flow (DCF) may not be appropriate for new technologies and early-stage investments.

On this episode of E2B: Energy to Business, an Opportune podcast, Voice of B2B, Daniel Litwin talked with James Hanson, Managing Director with Opportune Partners LLC, an independent investment banking and financial advisory affiliate of Opportune LLP. They broke down strategies for maneuvering early-stage investments in young companies, specifically around private equity investments in the energy sector.

Hanson has over 30 years of commercial and investment banking experience. He focused on traditional investment banking for the first half of his career, such as commercial lending. In the last 15 years, he spent his time on fairness opinions, solvency opinions, and valuations. Over the past decade, he has often seen the early-stage investment valuation question come up a lot.

“As we think about early-stage and venture investing, it kind of revolves around two aspects,” Hanson says. “The first would be new technologies. The second is along the lines of project finance.”

As Hanson explains, valuing an early-stage investment or technology is difficult terrain to predict since they often rarely have good comparables and have yet to produce significant cash flow or revenue. Financially, one new technology can be very different from another, making comparisons difficult. So, which valuation methodologies are the most effective for these early-stage investments? According to Hanson, a pragmatic method for valuing these types of companies and/or technologies is the cost-based approach (“Cost Approach”).

“It [the cost-based approach] ends up becoming less of throwing numbers on a spreadsheet exercise and more of a due diligence exercise,” Hanson says. “So, what we’ll do is typically talk to the management teams, talk to the people who are working on the products, and dig in to try to see what work has been done, what work needs to be done, what the plan is, where did you think it was before you started, etc.? It’s a case-by-case basis.”

Listen to hear more on private equity investment valuations in the energy sector.

Follow us on social media for the latest updates in B2B!

Image

Latest

Doable
Rethinking Leadership: Why “Doable” Might Be the Most Powerful Strategy in Education Today
April 3, 2026

At a time when educator burnout is rising and schools across the U.S. are facing ongoing teacher shortages, leaders are being forced to rethink what sustainable success actually looks like. Research shows that teacher attrition is closely tied to working conditions, job-related stress, and workload demands. As districts push for innovation, data-driven instruction, and…

Read More
Casey Brown
From Poverty to Pricing Power | Why Great Companies Undercharge
April 2, 2026

Casey Brown didn’t grow up thinking she would become an entrepreneur. She grew up in a blue-collar family where money was always tight — close enough to the edge that the fear of poverty shaped many of her early decisions. That fear led her into engineering, into corporate America, and eventually into a moment…

Read More
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
April 2, 2026

In this episode of Care Anywhere, host Lea Sims sits down with Nigerian nurse entrepreneur and advocate Obafemi Arowosegbe to discuss leadership, mentorship, and the future of nursing in Africa. While still a nursing student, Obafemi founded the Nightingale Summit, a growing conference designed to empower nursing students and early-career nurses with leadership skills,…

Read More
Oncology
From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation
April 1, 2026

The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians…

Read More